Discontinued — last reported Q4 '23

Investing

Acquired in-process research and development

Over 2 years (FY 2023 to FY 2025), Acquired in-process research and development shows a downward trend with a -100.0% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.

Analysis

StatementCash Flow Statement
SectionInvesting
CategoryGrowth
SignalHigher is better
VolatilityVolatile
First reportedQ1 2019
Last reportedQ4 2023

How to read this metric

High spending indicates a strong commitment to pipeline growth, though it carries significant execution and regulatory risk.

Detailed definition

Acquired In-Process Research and Development (IPR&D) represents the cash paid to acquire research projects that have not...

Peer comparison

A hallmark metric for pharmaceutical and biotech firms relying on external innovation.

Metric ID: acquired_ipr_d

Historical Data

3 years
 FY'23FY'24FY'25
Value$21.63M$0.00$0.00
YoY Change—-100.0%—
Range$0.00 – $21.63M
CAGR-100.0%
Avg YoY Growth-100.0%
Median YoY Growth-100.0%

Frequently Asked Questions

What is CRCL's acquired in-process research and development?
CRCL (CRCL) reported acquired in-process research and development of $0.00 in Q4 2025.
What is the long-term trend for CRCL's acquired in-process research and development?
Over 2 years (2023 to 2025), CRCL's acquired in-process research and development has grown at a -100.0% compound annual growth rate (CAGR), from $21.63M to $0.00.
What does acquired in-process research and development mean?
Cash spent to buy research and development projects from other companies.